Phosphodiesterase-4 inhibition in COPD

Lancet. 2009 Aug 29;374(9691):665-7. doi: 10.1016/S0140-6736(09)61538-5.
No abstract available

Publication types

  • Comment

MeSH terms

  • Aminopyridines / adverse effects
  • Aminopyridines / chemistry
  • Aminopyridines / therapeutic use*
  • Benzamides / adverse effects
  • Benzamides / chemistry
  • Benzamides / therapeutic use*
  • Bronchodilator Agents / therapeutic use
  • Cyclic Nucleotide Phosphodiesterases, Type 4 / physiology
  • Cyclopropanes / adverse effects
  • Cyclopropanes / chemistry
  • Cyclopropanes / therapeutic use
  • Drug Therapy, Combination
  • Humans
  • Patient Selection
  • Phosphodiesterase 4 Inhibitors*
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / enzymology
  • Pulmonary Disease, Chronic Obstructive / immunology
  • Research Design
  • Treatment Outcome

Substances

  • Aminopyridines
  • Benzamides
  • Bronchodilator Agents
  • Cyclopropanes
  • Phosphodiesterase 4 Inhibitors
  • Roflumilast
  • Cyclic Nucleotide Phosphodiesterases, Type 4